HIGHLY SENSITIVE SYSTEM AND METHODS FOR ANALYSIS OF PROSTATE SPECIFIC ANTIGEN (PSA)

• US 20090087860A1
• Filed: 08/22/2008
• Published: 04/02/2009
• Est. Priority Date: 08/24/2007
• Status: Abandoned Application

• Current Assignee: Singulex, Inc.
• Original Assignee: Singulex, Inc.
• Inventors: Lu, Ann, Todd, John A.
• Application Number:
  US12/197,159
• Publication Number:
  US 20090087860A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: G01N 2333/96455 Kallikrein (3.4.21.34; 3.4.21.35)
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/54 Determining the risk of relapse
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: G01N 33/57434 of prostate
• CPC Class Codes: G01N 33/58 involving labelled substances G01N33/53 takes precedence

Abstract

The invention described herein provides methods, compositions, kits, and systems for the sensitive detection of prostate specific antigen. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of prostate specific antigen.

Claims

1. A method for detecting a single prostate specific antigen (PSA) molecule, fragment, or complex in a sample at a level less that 100 pg/ml comprising:

a. labeling said PSA molecule, fragment, or complex, if present, with a label; and

b. detecting the presence or absence of said label, wherein detection of the presence of said label indicates the presence of said single PSA molecule, fragment, or complex of PSA in said sample.

2. The method of claim 1, wherein the level of PSA detected is less than 5 pg/ml.

3. The method of claim 1, wherein the level of PSA detected is less than 1 pg/ml.

4. The method of claim 1, wherein the level of PSA detected is less than 0.1 pg/ml.

5. The method of claim 1, wherein the PSA is selected from total PSA, free PSA, a PSA complex, PSA-ACT, and PSA-A2M.

6. The method of claim 1, wherein said detecting is capable of detecting said single molecules of PSA at a limit of detection of less than 100 pg/ml.

7. The method of claim 1, wherein said label comprises a fluorescent moiety.

8. The method of claim 7, wherein said fluorescent moiety comprises a dye selected from the group consisting of AlexaFluor 488, AlexaFluor 532, AlexaFluor 647, AlexaFluor 680, or AlexaFluor 700.

9. The method of claim 1, wherein said label further comprises a binding partner for said PSA molecule, fragment, or complex.

10. The method of claim 9, wherein said binding partner comprises an antibody specific to said PSA molecule, fragment, or complex.

11. The method of claim 1, further comprising capturing said PSA or PSA complex on a solid support.

12. The method of claim 11, wherein said solid support comprises a capture partner specific for said PSA or PSA complex that is attached to said solid support.

13. The method of claim 12, wherein said attachment of said capture partner to said solid support is selected from a noncovalent or covalent bond.

14. The method of claim 12, wherein said capture partner comprises an antibody.

15. The method of claim 1, wherein said label comprises a fluorescent moiety, and wherein step (b) comprises passing said label through a single-molecule detector.

16. The method of claim 15, wherein said single molecule detector comprises

a. an electromagnetic radiation source for stimulating said fluorescent moiety;

b. a capillary flow cell for passing said fluorescent moiety;

c. a source of motive force for moving said fluorescent moiety in said capillary flow cell;

d. an interrogation space defined within said capillary flow cell for receiving electromagnetic radiation emitted from said electromagnetic source;

e. an electromagnetic radiation detector operably connected to said interrogation space for measuring an electromagnetic characteristic of said stimulated fluorescent moiety; and

f. a microscope objective lens situated between said interrogation space and said detector, wherein the lens has a numerical aperture of 0.6 or greater.

17. A method of diagnosing prostate cancer based on levels of PSA wherein the level of PSA in a sample is detected at a level of sensitivity of less than 100 pg/ml.

18. The method of claim 17 wherein the diagnosis is of a recurrence of prostate cancer after surgical resection.

19. The method of claim 17 wherein the diagnosis of recurrence of prostate cancer is made by measuring the PSA levels from a series of samples.

20. The method of claim 17 wherein the diagnosis of recurrence of prostate cancer is made by measuring the change in levels of PSA in a series of samples.

21. A method for detecting a single prostate specific antigen (PSA) molecule, fragment, or complex in a sample at a level less that 5 pg/ml comprising:

a. labeling said PSA molecule, fragment, or complex, if present, with a label; and

b. detecting the presence or absence of said label, wherein detection of the presence of said label indicates the presence of said single PSA molecule, fragment, or complex of PSA in said sample.

22. The method of claim 21 wherein the level of PSA detected is in the range of about 0.1 pg/ml to about 1 pg/ml.

23. A method for assessing the likelihood of recurrence of cancer in an individual comprising:

a. determining a concentration of prostate specific antigen in a sample or determining the concentrations of prostate specific antigen in a series of samples from said individual, wherein the concentration is determined by a prostate specific antigen assay with a limit of detection of said prostate specific antigen in a sample less than about 5 pg/ml; and

b. determining the likelihood of recurrence of cancer for said individual, based on the concentration of prostate specific antigen in said sample, or in said concentrations of prostate specific antigen in said series of samples.

24. The method of claim 23 wherein step (b) further comprises measuring a change in concentration of prostate specific antigen in a sequential series of samples from said individual whereby said change is used to assess the likelihood or recurrence of cancer in said individual.

25. A method of monitoring decreases in a level of PSA after surgical resection comprising measuring the level of PSA in a first sample from an individual wherein said first sample is taken from said individual prior to surgical resection and further measuring the level of PSA in a second sample, said second sample taken from said individual after surgical resection is complete, and further comparing the levels of PSA in said first and second samples.

26. The method of claim 25 further comprising measuring the level of PSA in a series of samples taken from said individual after surgical resection and comparing the level of PSA from each sample from said series of sample to the level of PSA in said sample taken from said first sample.

27. A method of monitoring the effectiveness of a therapeutic treatment in an individual comprising measuring the level of PSA in a first sample from said individual wherein said first sample is taken prior to administration of said therapeutic treatment and further comprising measuring the level of PSA in a series of samples taken from said individual at different time points subsequent to beginning said therapeutic treatment and further comparing the level of PSA prior to said therapeutic treatment to the level of PSA subsequent to said therapeutic treatment to determine the effectiveness of said therapeutic treatment.

28. The method of claim 27 wherein said therapeutic treatment is altered in response to the level of PSA measured subsequent to said therapeutic treatment.

29. A method for diagnosing breast cancer in an individual comprising comparing a level of PSA in a sample obtained from said individual to a normal range of PSA levels wherein the normal range is determined from a distribution of PSA levels in a reference population consisting of normal individuals.

30. The method of claim 29 further comprising detecting levels of PSA in a sample at a sensitivity of less than 100 pg/ml.

31. A method for screening an individual for the presence of breast cancer comprising detecting a level of PSA in a series of samples taken from said individual and further detecting increases or decreases in PSA levels of said individual compared to a predetermined threshold level of PSA.

32. The method of claim 31 wherein PSA levels in the series of samples are detected at a level of sensitivity of less than 100 pg/ml.

33. A method of diagnosing a condition indicated by increased levels of kallikreins wherein the level of kallikreins in a sample is detected at a level of sensitivity of less than 100 pg/ml.

34. The method of claim 33 wherein the kallikrein detected is human killikrein 3 (hk3).

35. A method for determining a diagnosis, prognosis, or method of treatment in an individual comprising:

a. determining a concentration of prostate specific antigen in a sample or determining the concentrations of prostate specific antigen in a series of samples from said individual, wherein said concentration is determined by a prostate specific antigen assay with a limit of detection for said prostate specific antigen in a sample less than about 100 pg/ml; and

b. determining a diagnosis, prognosis, or method of treatment for said individual, based on said concentration of PSA in said sample, or on said concentrations of PSA in said series of samples.

36. The method of claim 35 wherein step (b) comprises a diagnosis, prognosis or method of treatment for an individual in which recurrence of prostate cancer has occurred.

37. The method of claim 35 wherein step (b) comprises a diagnosis, prognosis, or method of treatment for an individual having or susceptible to having breast cancer.

38. The method of claim 35 wherein step (b) comprises an analysis selected from the group consisting of comparing said concentration or series of concentrations to a normal value for said concentration, comparing said concentration or series of concentrations to a baseline value, and determining a rate of change of concentration for said series of concentrations.

39. The method of claim 35 wherein step (b) comprises comparing said concentration of PSA in a said sample with a predetermined threshold concentration, and determining a diagnosis, prognosis, or method of treatment if the sample concentration is greater than the threshold level.

40. A composition for the detection of a prostate specific antigen (PSA) molecule, fragment, or complex comprising a binding partner to the prostate specific antigen molecule, fragment, or complex attached to a fluorescent moiety, wherein said fluorescent moiety is capable of emitting at least about 200 photons when stimulated by a laser emitting light at the excitation wavelength of the moiety, wherein the laser is focused on a spot not less than about 5 microns in diameter that contains the moiety, and wherein the total energy directed at the spot by the laser is no more than about 3 microJoules.

41. The composition of claim 40 wherein said binding partner comprises an antibody to said PSA molecule, fragment, or complex.

42. The composition of claim 40 wherein said PSA is selected from free PSA, total PSA, or a PSA complex.

43. The composition of claim 42 wherein the PSA complex is selected from PSA-ACT and PSA-A2M.

44. The composition of claim 40 wherein said fluorescent moiety comprises a molecule that comprises at least one substituted indolium ring system in which the substituent on the 3-carbon of the indolium ring contains a chemically reactive group or a conjugated group.

45. The composition of claim 40 wherein said fluorescent moiety comprises a dye selected from the group consisting of AlexaFluor 488, AlexaFluor 532, AlexaFluor 647, AlexaFluor 680, AlexaFluor 700.

46. A composition comprising a set of standards for the determination of a concentration of a PSA wherein at least one of the standards is at a concentration of PSA less than about 100 pg/ml.

47. A kit comprising a composition comprising an antibody to prostate specific antigen attached to a fluorescent dye moiety, wherein said moiety is capable of emitting at least about 200 photons when stimulated by a laser emitting light at the excitation wavelength of the moiety, wherein the laser is focused on a spot not less than about 5 microns in diameter that contains the moiety, and wherein the total energy directed at the spot by the laser is no more than about 3 microJoules, wherein said composition is packaged in suitable packaging.

48. The kit of claim 47 wherein the PSA is free PSA, total PSA, or a PSA complex.

49. The kit of claim 48 wherein the complexed PSA is selected from PSA-ACT or PSA-A2M.

50. The kit of claim 47 further comprising a composition comprising a capture antibody attached to a solid support.

51. The kit of claim 47 further comprising a composition comprising a capture antibody for complexed PSA attached to a solid support.

52. The kit of claim 51 wherein said solid support comprises a microtiter plate or paramagnetic microparticles.

53. The kit of claim 47 further comprising a component selected from the group consisting of wash buffer, assay buffer, elution buffer, and calibrator diluent.

54. The kit of claim 47 further comprising a standard for the PSA.